Novo Nordisk launches national Wegovy campaign

Novo Nordisk has introduced "The Power of Wegovy®," a national campaign designed to educate the public on the clinical benefits of Wegovy® (semaglutide) 2.4 mg injection and to highlight diverse, personal weight-management journeys. This campaign aims to empower individuals living with obesity, addressing the stigma associated with weight and emphasizing the importance of partnership with healthcare professionals. Wegovy® is prescribed alongside a reduced-calorie diet and increased physical activity to help adults manage their weight and reduce the risk of major cardiovascular events, such as heart attack or stroke.

The campaign coincides with a recent update to Wegovy®'s FDA-approved label, which now includes a cardiovascular risk reduction indication and has removed body mass index descriptors from its weight-management indication. Novo Nordisk is focused on ensuring access to Wegovy® aligns with these new indications and is expanding efforts to increase overall coverage for obesity medications. This includes recent Centers for Medicare and Medicaid Services (CMS) guidance to cover Medicare Part D patients who are living with obesity and have known heart disease. Despite improved coverage, Novo Nordisk acknowledges that supply and cost remain challenges, and they continue to monitor market dynamics to address these issues.

Novo Nordisk is committed to the responsible use of Wegovy® and emphasizes that it should not be used with other semaglutide-containing products. The campaign encourages patients to discuss insurance coverage and medication costs with their healthcare providers, noting that many commercially insured patients can access Wegovy® at a reduced cost. The company also highlights potential side effects and important safety information, reinforcing the need for informed, patient-centered care in managing obesity and related health risks.

Click here to read the original news story.